Alexion Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Alexion Pharmaceuticals generated cash of $3,002,900,000, which is more than the previous year. Cash used in financing activities reached the amount of -$611,900,000 last year. Net change in cash is therefore $311,000,000.
Cash Flow
| 2011 | 270.08M | -33.71M | 39.05M |
|---|---|---|---|
| 2012 | 410.61M | -627.58M | 666.37M |
| 2013 | 497.34M | -1.02B | 71.63M |
| 2014 | 640.07M | -222.86M | 7.12M |
| 2015 | 675.19M | -3.58B | 2.98B |
| 2016 | 1.08B | -287M | -836M |
| 2017 | 1.11B | -918.3M | -596.6M |
| 2018 | 426M | 470.5M | -102.4M |
| 2019 | 2.08B | 9.7M | -739.1M |
| 2020 | 3.00B | -2.09B | -611.9M |
ALXN Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.72B | 1.36B | 584.4M | 966M | 1.01B | 943.99M | 529.85M | 989.50M | 540.86M | 267.14M |
Operating activities | ||||||||||
Net income | 603.4M | 2.40B | 77.6M | 443.3M | 399M | 144.38M | 656.91M | 252.89M | 254.82M | 175.31M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 329.4M | 376.8M | 405.3M | 496.7M | 396M | 166.62M | 46.93M | 28.69M | 23.88M | 17.61M |
Stock-based compensation expense | 281.1M | 237M | 203M | 243.1M | 192M | 227.13M | 114.46M | 76.20M | 54.01M | 44.76M |
| Deferred income tax benefit | 281.1M | 237M | 203M | 243.1M | 192M | 227.13M | 114.46M | 76.20M | 54.01M | 44.76M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -139.4M | -319.2M | -208.8M | -55.2M | -122M | -115.81M | -28.13M | -116.43M | -72.87M | -78.77M |
Inventories | 95M | -156.9M | -14.7M | -88.2M | -84M | -88.37M | -66.81M | 126K | -6.26M | -12.17M |
Accounts payable | -4.19B | -3.68B | -2.42B | -2.02B | -1.68B | -1.91B | -1.93B | -1.48B | 0 | 0 |
Cash generated by operating activities | 3.00B | 2.08B | 426M | 1.11B | 1.08B | 675.19M | 640.07M | 497.34M | 410.61M | 270.08M |
Investing activities | ||||||||||
Purchases Of Investments | -77.2M | -171.1M | -805.1M | -1.65B | -675M | -534.70M | -705.15M | -1.04B | 0 | 0 |
Investments In Property Plant And Equipment | -106.7M | -170.7M | -213M | -357.3M | -333M | -286.33M | -136.65M | -29.32M | -21.84M | -21.98M |
Acquisitions Net | -2.11B | 114.7M | 0 | 0 | 0 | -3.93B | 0 | 0 | -605.73M | -105.88M |
Cash generated by investing activities | -2.09B | 9.7M | 470.5M | -918.3M | -287M | -3.58B | -222.86M | -1.02B | -627.58M | -33.71M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 462.21M | 35.76M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -510.8M | -416M | -85M | -463.6M | -430M | -327.69M | -302.59M | -66.13M | -11.55M | 0 |
Repayments of term debt | -130.6M | 0 | -293.8M | 0 | -375M | 0 | -55.5M | -36M | -206M | -60.73M |
Cash used in financing activities | -611.9M | -739.1M | -102.4M | -596.6M | -836M | 2.98B | 7.12M | 71.63M | 666.37M | 39.05M |
Net Change In Cash | 311M | 1.35B | 782.9M | -381.6M | -44M | 66.11M | 414.14M | -459.64M | 448.63M | 273.72M |
Cash at end of period | 3.03B | 2.72B | 1.36B | 584.4M | 966M | 1.01B | 943.99M | 529.85M | 989.50M | 540.86M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |